Nafld Clinical Trials 2023

What are the top hospitals conducting nafld research?

Amidst the rapidly growing concern over non-alcoholic fatty liver disease (NAFLD), several top hospitals have emerged as trailblazers in the field of clinical trials. In New York, Columbia University Irving Medical Center leads the way with two active NAFLD trials and a total of three completed studies dedicated to this condition. This institution made its mark by recording its first trial in 2023, demonstrating their commitment to advancing our understanding and treatment options for NAFLD. Similarly, Duke University Medical Center in Durham has been actively involved in tackling NAFLD since 2005 when they initiated their first trial. With two ongoing trials and an impressive track record of 27 previous investigations, Duke's efforts are helping shape the future management of this increasingly prevalent liver disease.

Meanwhile, at Mayo Clinic located in Rochester, Minnesota, research into NAFLD is also gaining momentum. Since commencing their initial trial in 2020, Mayo Clinic has currently undertaken two active trials while contributing to a cumulative total of three studies on this condition thus far. On the other side of Texas lies Worldwide Clinical Trials' Early Phase Services LLC based in San Antonio—a facility that may be smaller scale but nonetheless plays a crucial role within the landscape of NAFLD research. Having recorded its inaugural study on NALFD only recently in 2023 along with one current active trial underway; it proves that significant contributions can come from various institutions regardless size or location.

Lastly representing West Coast excellence is University of California, Minneso In New York, Columbia University Irving Medical Center leads the way with two active NAFLD trials and a total of three completed studies dedicated to this condition. This institution made its mark by recording its first trial in 2023, demonstrating their commitment to advancing our understanding and treatment options for NAFLD. Similarly, Duke University Medical Center in Durham has been actively involved in tackling NAFLD since 2005 when they initiated their first trial. With two ongoing trials and an impressive track record of 27 previous investigations, Duke's efforts are helping shape the future management of this increasingly prevalent liver disease.

Meanwhile, at Mayo Clinic located in Rochester, Minnesota, research into NAFLD is also gaining momentum. Since commencing their initial trial in 2020, Mayo Clinic has currently undertaken two active trials while contributing to a cumulative total of three studies on this condition thus far. On the other side of Texas lies Worldwide Clinical Trials' Early Phase Services LLC based in San Antonio—a facility that may be smaller scale but nonetheless plays a crucial role within the landscape of NAFLD research. Having recorded its inaugural study on NALFD only recently in 2023 along with one current active trial underway; it proves that significant contributions can come from various institutions regardless size or location.

Lastly representing West Coast excellence is University of California, San Diego situated uniquely amidst picturesque La Jolla scenery where they have conducted eight all-time nafld clinical examinations so far while having one presently running investigation set up . Their journey began backin2009 when UCSD launched their maiden experiment focused solely on addressing Non-Alcoholic Fatty Liver Disease .

Together these leading hospitals demonstrate an unwavering dedication towards combating such ailments through innovative research approaches—each step toward unravelling secrets of NAFLD brings us closer to finding effective interventions and therapies for millions suffering worldwide.

Which are the best cities for nafld clinical trials?

When it comes to NAFLD clinical trials, several cities in the United States are at the forefront of research and innovation. San Antonio, Texas leads with 10 active trials investigating treatments like Resmetirom, Intervention/Drug, and Saroglitazar Magnesium 4 mg Tablet. Following closely behind are Chicago, Illinois and New York, Illinois and New York, New York with 5 ongoing studies each exploring interventions such as Efinopegdutide 4mg and Lisinopril. Additionally, Dallas, Texas and Tucson Arizona have 4 active trials focusing on Resmetirom, Efinopegdutide 4mg, and other potential therapies. These cities offer individuals affected by NAFLD access to cutting-edge clinical trials that may shape future treatment options for this complex condition.

Which are the top treatments for nafld being explored in clinical trials?

Clinical trials are paving the way for advancements in treating non-alcoholic fatty liver disease (NAFLD). Among the top contenders is semaglutide, currently being explored in two active trials. Since its first listing in 2016, it has become a subject of interest with a total of 11 NAFLD trials. Another promising treatment on the horizon is diazoxide oral suspension at a dosage of 1 mg per kg per dose, which is currently under investigation in one active trial and marks its debut on the clinical trial scene in 2023. These innovative approaches hold promise for improving outcomes and addressing this challenging condition.

What are the most recent clinical trials for nafld?

Important advancements are being made in the field of non-alcoholic fatty liver disease (NAFLD) through recent clinical trials. These studies aim to improve our understanding and treatment options for NAFLD, a condition characterized by excessive fat accumulation in the liver. Some of the most recent trials include evaluating the reduction toward euinsulinemia (RE) protocol, LY3885125, BI 3006337 dose group 4, diazoxide oral suspension, and bicalutamide for NAFLD patients. These trials focus on different approaches to address various aspects of the disease and have become available throughout August 2023. Through these ongoing investigations, we hope to uncover new strategies that will enhance patient outcomes and contribute to managing this prevalent health issue more effectively.

What nafld clinical trials were recently completed?

Numerous clinical trials focused on NAFLD have recently reached completion, demonstrating the commitment of researchers in addressing this prevalent liver condition. Among these trials are ALT-801 sponsored by Altimmune, Inc., which concluded in both March 2022 and September 2021; BIO89-100 sponsored by 89bio, Inc., completed in August 2021; Efinopegdutide 20 mg/mL sponsored by Merck Sharp & Dohme Corp., wrapped up in August 2021; AMG 609 sponsored by Amgen was finalized in May 2021; TERN-201 conducted under the sponsorship of Terns, Inc., achieved completion also in May 2021. Additionally, several other significant trials were successfully completed between November 2020 to December 2019 involving various pharmaceutical sponsors such as Oramed Ltd., National Institute of Allergy and Infectious Diseases (NIAID), Genentech Inc., Pfizer, NGM Biopharmaceuticals Inc., Novartis Pharmaceuticals, and Madrigal Pharmaceuticals Inc. These collective efforts underline the continuous pursuit for effective treatments for NAFLD.